Abstract
Although preliminary data suggest that use of β2-agonist in the context of ARDS could potentially accelerate alveolar edema clearance and have beneficial anti-inflammatory and immunomodulatory effects, robust prospective clinical trials demonstrated that use of β2-agonists in ARDS patients is unlikely to be beneficial and could worsen outcomes. Routine administration of β2-agonists in mechanically ventilated critically ill patients with ARDS should therefore be avoided.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rubenfeld GD, Caldwell E, Peabody E et al (2005) Incidence and outcomes of acute lung injury. N Engl J Med 353:1685–1693
Matthay MA, Ware LB, Zimmerman GA (2012) The acute respiratory distress syndrome. J Clin Invest 122:2731–2740
Mutlu GM, Sznajder JI (2005) Mechanisms of pulmonary edema clearance. Am J Physiol Lung Cell Mol Physiol 289:685–695
Mutlu GM, Adir Y, Jameel M et al (2005) Interdependency of beta-adrenergic receptors and CFTR in regulation of alveolar active Na1 transport. Circ Res 96:999–1005
Sartori C, Allemann Y, Duplain H et al (2002) Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 346:1631–1636
Manocha S, Gordon AC, Salehifar E et al (2006) Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Crit Care 10:R12
Perkins GD, McAuley DF, Thickett DR, Gao F (2006) The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 173:281–287
Gao Smith F, Perkins GD, Gates S, BALTI-2 Study Investigators et al (2012) Effect of intravenous b-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomized controlled trial. Lancet 379:229–235
Matthay MA, Brower RG, Carson S, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network et al (2011) Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 184:561–568
Perkins GD, Gates S, Park D, Gao F et al; BALTI-Prevention Collaborators (2014) The beta agonist lung injury trial prevention: a randomized controlled trial. Am J Respir Crit Care Med 189:674–683
Johnson M (2006) Molecular mechanisms of beta (2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117:18–24
Mutlu GM, Factor P (2008) Alveolar epithelial beta2-adrenergic receptors. Am J Respir Cell Mol Biol 38:127–134
Bassford CR, Thickett DR, Perkins GD (2012) The rise and fall of β-agonists in the treatment of ARDS. Crit Care 16(2):208
Berthiaume Y, Matthay MA (2007) Alveolar edema fluid clearance and acute lung injury. Respir Physiol Neurobiol 159:350–359
Perkins GD, McAuley DF, Richter A et al (2004) Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome. Crit Care 8:25–32
Perkins GD, Gao F, Thickett DR (2008) In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 63:215–220
Bloemen PG, van den Tweel MC, Henricks PA et al (1997) Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 272:580–587
Perkins GD, Nathani N, McAuley DF et al (2007) In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax 62:36–42
Tan KS, Nackley AG, Satterfield K et al (2007) Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 19:251–260
Cazzola M, Page CP, Calzetta L, Matera MG (2012) Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64(3):450–504
Morgan DJ, Paull JD, Richmond BH et al (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22(5):587–593
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Zochios, V. (2015). Does β2-Agonist Use Improve Survival in Critically Ill Patients with Acute Respiratory Distress Syndrome?. In: Landoni, G., Mucchetti, M., Zangrillo, A., Bellomo, R. (eds) Reducing Mortality in Critically Ill Patients. Springer, Cham. https://doi.org/10.1007/978-3-319-17515-7_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-17515-7_13
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17514-0
Online ISBN: 978-3-319-17515-7
eBook Packages: MedicineMedicine (R0)